A Long-term Efficacy and Safety Study of Tramadol Hydrochloride Plus Acetaminophen (JNS013) in Japanese Participants With Chronic Pain
A Study of a Long-term Administration of JNS013 in Patients With Chronic Pain
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Chikushi, Japan
-
Chuo, Japan
-
Fukui, Japan
-
Fukuoka, Japan
-
Hiratsuka, Japan
-
Ichikawa, Japan
-
Kashiwa, Japan
-
Komatsu, Japan
-
Kuki, Japan
-
Kumamoto, Japan
-
Kyoto, Japan
-
Mihara, Japan
-
Nagoya, Japan
-
Nerima, Japan
-
Obihiro, Japan
-
Ogi, Japan
-
Ohta-Ku, Japan
-
Osaka, Japan
-
Tagawa, Japan
-
Taito-Ku, Japan
-
Takaoka, Japan
-
Tokyo, Japan
-
Tokyo N/A, Japan
-
Urayasu, Japan
-
Yame, Japan
-
Yokohama, Japan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants whose pain cannot be controlled sufficiently with at least 14-day continuous treatment with identical oral non steroid anti inflammatory drugs (NSAIDs) at a usual maximum dose during 3 months prior to this study
- Ambulatory participants without need for any supportive device or assistance during daily life
- Outpatients
- Participants who do not plan to change the therapeutic policy and content of the medications for underlying disease during screening period to the end of Treatment Period I
- Sustention of chronic pain due to Osteo Arthritis (OA), Low Back Pain (LBP), Rheumatoid Arthritis (RA), Neck Shoulder Arm Syndrome (NSAS), Diabetic Neuropathy (DN), Post herpetic Neuralgia (PHN) or other for at least 3 months
Exclusion Criteria:
- Participants with conditions for which opioids are contraindicated
- Participants with conditions for which APAP are contraindicated
- Participants with history of convulsion or the possibility of convulsive seizure
- Participants with concurrent, previous, or possible alcohol dependence, drug dependence, or narcotic addiction
- Pregnant Participants or those who may be pregnant, lactating mothers, and Participants who wish pregnancy during the study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Tramadol HCL plus Acetaminophen
|
Tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg (JNS013) one or two tablets will be given orally four times daily (maximum dose is 8 tablets per day) for 4 weeks during treatment period 1 (restrictions on concomitant treatments will be established) and for 48 weeks during treatment period 2 (permitting modifications to the concomitant drugs/therapies).
The dosing interval will be of at least 4 hours.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Visual Analogue Scale (VAS24) Score at Week 4
Time Frame: Baseline and Week 4
|
Pain over the last 24 hours was assessed by using VAS score ranges from 0 millimeter (mm)=no pain to 100 mm=worst possible pain.
An increase in score from baseline represented disease progression and decrease represented improvement.
|
Baseline and Week 4
|
|
Change From Baseline in VAS24 Score at Week 52
Time Frame: Baseline and Week 52
|
Pain over the last 24 hours was assessed by using VAS score ranges from 0 mm=no pain to 100 mm=worst possible pain.
An increase in score from baseline represented disease progression and decrease represented improvement.
|
Baseline and Week 52
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Improvement From Baseline in VAS24 Score
Time Frame: Week 4 and 52
|
Pain over the last 24 hours was assessed by using VAS score ranges from 0 mm=no pain to 100 mm=worst possible pain.
An increase in score from baseline represented disease progression and decrease represented improvement.
|
Week 4 and 52
|
|
Pain Intensity Difference (PID) at Week 4
Time Frame: Week 4
|
PID is defined as the amount of change in the pain intensity at each evaluation time point (at 2 and 4 hours after the study drug dosing) from the baseline for each participant.
Pain Intensity was evaluated on a 4-stage scale ranging from 3=severe pain to 0=no pain.
PID ranges from -3 (the worst) to +3 (the most improved).
|
Week 4
|
|
Pain Relief (PAR) Score at Week 4
Time Frame: Week 4
|
Pain relief was evaluated based on a 5-stage scale from 4 (complete relief) to 0 (no relief).
An increase in score represented improvement and decrease represented disease progression
|
Week 4
|
|
Pain Relief Combined With Pain Intensity Difference (PRID) at Week 4
Time Frame: Week 4
|
PRID was sum of the PID and PAR for each participant at each evaluation time point (2 hours after dosing, 4 hours after dosing).
Pain Intensity was evaluated on a 4-stage scale ranges from 3=severe pain to 0=no pain and PID ranges from -3 (the worst) to +3 (the most improved).
PAR ranges from 0 (no improved) to +4 (the most improved).
PRID ranges from -3 (the worst) to +7 (the most improved).
|
Week 4
|
|
Change From Baseline in Short Form-36 (SF-36) Score
Time Frame: Baseline, Week 4 and 52
|
SF-36 is a metric for general health and Quality of Life (QOL), consists of 8 sub-scale indices related to health and QOL (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health).
Each of the sub-scale scores ranged from 0 to 100, where higher values indicate a better health status or a better mental status.
|
Baseline, Week 4 and 52
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CR015115
- JNS013-JPN-05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.